Overview

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

Status:
Terminated
Trial end date:
2019-05-23
Target enrollment:
Participant gender:
Summary
The aim of this study is to demonstrate the efficacy and to evaluate the safety, pharmacokinetics (PK) and immunogenicity of anakinra in patients with newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic arthritis) and AOSD (Adult-onset Still's disease).
Phase:
Phase 3
Details
Lead Sponsor:
Swedish Orphan Biovitrum
Treatments:
Interleukin 1 Receptor Antagonist Protein